Clinical and Translational Oncology (2023) 25:560–562
https://doi.org/10.1007/s12094-022-03020-5

CORRECTION

Correction to: Therapeutic benefits of niraparib tosylate as radio sensitizer in esophageal squamous cell carcinoma: an in vivo and in vitro preclinical study

Yuzhong Cui[1,2,3,4,5] · Wei Huang[6,7] · Feng Du[5] · Xiaoyang Yin[6,7] · Lei Feng[6,7] · Baosheng Li[6,7]

Published online: 6 December 2022

Correction to: Clinical and Translational Oncology (2022) 24:1643–1656
https://doi.org/10.1007/s12094-022-02818-7

Following publication of this article, errors were identified in Fig. 4; specifically:

- Fig. 4-2B: in the immunofluorescence of K150-BCL2-24H, the following images were originally duplicated in error:
  - Combination (second row)
  - Niraparib Tosylate (3rd row)
- Fig. 4-2C: in the immunofluorescence of K30-γH2AX(24H), the following image was originally duplicated in error:
  - Radiation (1st row)

The images have been replaced with the correct images from the raw data.

The corrections do not have any effect on the final conclusions of the paper. The original article has been corrected.

The original article can be found online at https://doi.org/10.1007/s12094-022-02818-7.

✉ Baosheng Li
bsli@sdfmu.edu.cn

1 Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China

2 National Clinical Research Center for Cancer, Tianjin 300060, China

3 Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

4 Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

5 Department of Oncology, Zibo Municipal Hospital, Zibo 255400, China

6 Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China

7 Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Huaiyin District, Jinan 250117, Shandong, China


2
A
KYSE30-BAX-24H
Control
Niraparib Tosylate
Radiation
Combination
B
KYSE30-BCL2-24H
KYSE150-BAX-24H
KYSE150-BCL2-24H
C
KYSE30-rH2AX-24H
KYSE150-rH2AX-24H
3
A
K30
mRNA relative expression level
Bcl-2
BAX
caspase-3
B
K150

Figure 4 (2) **A** Immunofluorescence of γH2AX. **B** Immunofluorescence of BAX. **C** Immunofluorescence of BCL-2. (3) mRNA relative expression level among the four groups for **A** KYSE-30 cell line. **B** KYSE-150 cell line. $*P < 0.05$, $**P < 0.01$